Transcription factor mediated programming towards megakaryocytes
This invention relates to the forward programming of pluripotent stem cells (PSCs) into megakaryocyte (MK) progenitor cells using the transcription factors GATA1, FLI1 and TAL1. Methods of producing megakaryocyte (MK) progenitor cells and subsequently differentiating them into mature megakaryocytes are provided.
1. A method of producing megakaryocyte progenitor cells comprising;
(i) transducing isolated human pluripotent stem cells (hPSCs) concurrently with a nucleic acid encoding GATA binding protein 1 (GATA1), Friend leukemia virus integration 1 (FLI1) and T cell acute lymphocytic leukemia protein 1 (TAL1) transcription factors into a population of isolated human pluripotent stem cells (hPSCs);
(ii) culturing the transduced hPSCs of step (i) without feeder cells in a mesoderm chemically defined medium (CDM) comprising one or more of Activin-A, FGF2 of BMP4 for 1 or more days, thereby inducing mesoderm progenitor cells; and
(iii) culturing the mesoderm progenitor cells of step (ii) in megakaryocyte (MK) programing culture medium without feeder cells and comprising one or more of recombinant proteins (Thrombopoietin) TPO, Stem Cell Factor (SCF) or IL-beta (ILB), wherein the combination of GATA1, FLI1 and TAL1 transcription factors is expressed, such that one or more cells in the population are programmed into megakaryocyte progenitor cells that express at least CD41a.
2. The method according to claim 1 wherein the transcription factors are human transcription factors.
3. The method according to claim 1 , wherein the megakaryocyte progenitor cells express CD34 and CD41a.
4. The method according to claim 1 wherein the nucleic acid further encodes two, three or more of IKZF1, HOXA5, RUNX1, ZFPM2, ZFPM1 and GATA2 transcription factors; or two, three or more of ABLIM1, FHL1, RUNX3, NFIC, NFIL3, VDR, MESP1, BTBD11, APPL2, MICAL1, BATF, SCMH1 and MBP transcription factors.
5. The method according to claim 1 wherein the nucleic acid encodes a combination of transcription factors, wherein the combination of transcription factors consists of GATA 1, FLI1 and TAL1.
6. The method according to claim 1 comprising isolating and/or purifying said megakaryocyte progenitor cells.
7. The method according to claim 6 comprising expanding the population of megakaryocyte progenitor cells.
8. The method according to claim 6 comprising storing the population of megakaryocyte progenitor cells.
9. The method according to claim 1 , further comprising culturing the megakaryocyte progenitor cells in a megakaryocyte maturation medium comprising TPO and/or SCF and/or IL1-beta (ILB) to produce mature megakaryocyte cells.
10. The method according to claim 9 wherein the megakaryocyte progenitor cells are cultured in MK maturation medium comprising TPO and/or SCF and/or IL1-beta to produce said mature megakaryocyte cells.
11. The method according to claim 9 wherein the mature megakaryocyte cells are CD61+, CD34+ or CD34−, CD41a+, CD42a+, CD42b+.
12. The method according to claim 9 comprising isolating and/or purifying said mature megakaryocyte cells.
13. The method according to claim 9 further comprising causing or allowing one or more of said mature megakaryocyte cells to produce platelets and/or platelet size particles co-expressing CD41a and CD42a.
14. The method according to claim 1 wherein the human pluripotent stem cells are ES cells, iPS cells, fetal or adult somatic stem cells, or haematopoietic stem cells and progenitors.
15. The method according to claim 1 wherein the pluripotent stem cells are hiPS cells derived from a sample of normal cells obtained from an individual or a sample of cells having a disease associated phenotype or genotype obtained from an individual.